Form 4: DURECT Director Disposes Shares Post-Merger

DURECT Corporation's Director, Peter S. Garcia, reported the disposition of common stock and stock options following the company's merger with Bausch Health Americas, Inc.

Summary

• DURECT Corporation completed a merger with Bausch Health Americas, Inc. (Parent) and its subsidiary BHC Lyon Merger Sub, Inc. (Purchaser), effective September 11, 2025.
• Prior to the merger, Purchaser completed a tender offer for DURECT's Common Stock.
• Stockholders who tendered their shares received $1.75 per share in cash, plus one non-tradeable contingent value right (CVR) per share.
• CVRs entitle holders to a pro rata portion of two milestone payments, totaling up to $350,000,000, upon achievement of specified milestones.
• Director Peter S. Garcia disposed of 12,500 shares of common stock and 18,000 stock options (7,000 at $9.8, 5,500 at $5.46, 5,500 at $5.29) on September 11, 2025, as a result of the merger.
• Stock options with an exercise price less than $1.75 were accelerated and exercised, with the resulting shares participating in the tender offer.
• Stock options with an exercise price equal to or greater than $1.75 were canceled, with former holders eligible for a cash retention bonus tied to net sales milestones.

Sentiment

Score: 7

Explanation: The filing reports the expected outcome of a merger, providing shareholders with cash and potential future upside via CVRs. While the company ceases to be independent, the terms appear structured to offer value to former shareholders and provide retention incentives for key personnel.

Positives

• Shareholders received a cash consideration of $1.75 per share, providing immediate liquidity.
• Shareholders also received contingent value rights (CVRs) offering potential upside of up to $350,000,000 based on future milestone achievements.
• Certain stock options were accelerated and exercised, allowing holders to participate in the tender offer.
• Holders of out-of-the-money options are eligible for a cash retention bonus, providing a potential benefit despite option cancellation.

Negatives

• DURECT Corporation ceased to be an independent publicly traded entity, becoming a wholly owned subsidiary of Bausch Health Americas, Inc.
• Director Peter S. Garcia no longer beneficially owns common stock or stock options in DURECT Corporation.
• The contingent value rights are non-tradeable, limiting liquidity for the potential future milestone payments.
• Stock options with an exercise price equal to or greater than the cash amount ($1.75) were canceled, potentially resulting in a loss for holders if the stock price had risen above their strike price in the future.

Risks

• Achievement of the contingent value right (CVR) milestone payments is uncertain and dependent on future net sales milestones.
• The CVRs are non-tradeable, meaning holders cannot sell them for immediate value, and their value is entirely dependent on future events.
• The cash retention bonus for canceled options is subject to the achievement of certain net sales milestones, introducing uncertainty for recipients.

Future Outlook

The future financial performance of DURECT Corporation will be consolidated under Bausch Health Americas, Inc. The potential for additional payments to former DURECT shareholders is contingent upon the achievement of specified net sales milestones, which could result in up to $350,000,000 in aggregate milestone payments.

Industry Context

This transaction represents a consolidation within the pharmaceutical or biotech sector, where larger entities acquire smaller companies to expand their product pipelines or market share. The use of contingent value rights (CVRs) is a common mechanism in such acquisitions to bridge valuation gaps and share future risks/rewards, particularly in industries with long development cycles and uncertain product success.

Stakeholder Impact

• Shareholders: Received cash consideration and contingent value rights, providing immediate value and potential future upside, but losing direct equity in a public company.
• Employees (Option Holders): Those with in-the-money options benefited from acceleration and participation in the tender offer; those with out-of-the-money options are eligible for retention bonuses, providing an incentive to remain with the acquired entity.
• Company (DURECT): Ceased to be an independent public entity, becoming a wholly-owned subsidiary of Bausch Health Americas, Inc.
• Acquirer (Bausch Health Americas, Inc.): Successfully acquired DURECT, expanding its portfolio.

Next Steps

• Monitoring the achievement of specified net sales milestones for the contingent value rights.
• Former holders of canceled stock options will await details regarding their eligibility and achievement of cash retention bonuses.

Key Dates

Keywords

DURECT, DRRX, Bausch Health, Merger, Tender Offer, Contingent Value Right, CVR, Stock Option, Insider Transaction, Form 4, Acquisition, Pharmaceutical, Biotech